SI1853721T1 - Postopek za ugotavljanje odzivnosti na CHK inhibitorje - Google Patents
Postopek za ugotavljanje odzivnosti na CHK inhibitorjeInfo
- Publication number
- SI1853721T1 SI1853721T1 SI200630659T SI200630659T SI1853721T1 SI 1853721 T1 SI1853721 T1 SI 1853721T1 SI 200630659 T SI200630659 T SI 200630659T SI 200630659 T SI200630659 T SI 200630659T SI 1853721 T1 SI1853721 T1 SI 1853721T1
- Authority
- SI
- Slovenia
- Prior art keywords
- chk1
- patient
- chk1 inhibitors
- determining responsiveness
- signal transduction
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000004043 responsiveness Effects 0.000 title abstract 2
- 101150050673 CHK1 gene Proteins 0.000 title 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 abstract 4
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 abstract 4
- 230000019491 signal transduction Effects 0.000 abstract 2
- 239000012623 DNA damaging agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65413105P | 2005-02-18 | 2005-02-18 | |
PCT/GB2006/000548 WO2006087557A1 (en) | 2005-02-18 | 2006-02-16 | METHOD FOR DETERMINING RESPONSIVENESS TO CHKl INHIBITORS |
EP06709785A EP1853721B1 (en) | 2005-02-18 | 2006-02-16 | Method for determining responsiveness to chk1 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SI1853721T1 true SI1853721T1 (sl) | 2010-06-30 |
Family
ID=36295309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200630659T SI1853721T1 (sl) | 2005-02-18 | 2006-02-16 | Postopek za ugotavljanje odzivnosti na CHK inhibitorje |
Country Status (24)
Country | Link |
---|---|
US (1) | US20080145358A1 (sl) |
EP (1) | EP1853721B1 (sl) |
JP (1) | JP2008530575A (sl) |
KR (1) | KR20070107034A (sl) |
CN (1) | CN101120096A (sl) |
AT (1) | ATE464395T1 (sl) |
AU (1) | AU2006215413B2 (sl) |
BR (1) | BRPI0607798A2 (sl) |
CA (1) | CA2598185A1 (sl) |
CY (1) | CY1110076T1 (sl) |
DE (1) | DE602006013604D1 (sl) |
DK (1) | DK1853721T3 (sl) |
ES (1) | ES2341796T3 (sl) |
HK (1) | HK1113059A1 (sl) |
HR (1) | HRP20100313T1 (sl) |
IL (1) | IL184873A0 (sl) |
MX (1) | MX2007010073A (sl) |
NO (1) | NO20074610L (sl) |
NZ (1) | NZ556718A (sl) |
PL (1) | PL1853721T3 (sl) |
PT (1) | PT1853721E (sl) |
SI (1) | SI1853721T1 (sl) |
WO (1) | WO2006087557A1 (sl) |
ZA (1) | ZA200706670B (sl) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2086580A2 (en) * | 2006-11-21 | 2009-08-12 | Merial Limited | Prime boost canine leishmania vaccine |
WO2008121766A1 (en) | 2007-03-29 | 2008-10-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Genetic changes in atm and atr/chek1 as prognostic indicators in cancer |
US8173366B2 (en) | 2007-03-29 | 2012-05-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Genetic changes in ATM and ATR/CHEK1 as prognostic indicators in cancer |
GB0720113D0 (en) * | 2007-10-15 | 2007-11-28 | Cambridge Cancer Diagnostics L | Diagnostic, prognostic and predictive testing for cancer |
JP5436786B2 (ja) * | 2008-03-06 | 2014-03-05 | オリンパス株式会社 | 細胞周期計測方法 |
WO2010076887A1 (en) * | 2009-01-05 | 2010-07-08 | Banyu Pharmaceutical Co.,Ltd. | Predictive biomarkers useful for cancer therapy mediated by a wee1 inhibitor |
WO2016126616A1 (en) | 2015-02-02 | 2016-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and kits for measuring and quantifying dna double-stranded breaks using gamma-h2ax and h2ax |
JP2019514396A (ja) * | 2016-05-05 | 2019-06-06 | ナントミクス,エルエルシー | チェックポイント不全およびそれに関する方法 |
WO2018030547A1 (ja) * | 2016-08-12 | 2018-02-15 | 日立化成株式会社 | 血中循環癌細胞の検出方法及び血中循環癌細胞を検出するための前処理方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001161398A (ja) * | 1999-12-06 | 2001-06-19 | Igaku Seibutsugaku Kenkyusho:Kk | タンパク質リン酸化酵素の活性測定方法およびタンパク質リン酸化酵素の活性測定キット |
ES2309484T3 (es) * | 2003-01-09 | 2008-12-16 | Pfizer Inc. | Derivados de diazepinoindol como inhibidores de quinasa. |
BRPI0408256A (pt) * | 2003-03-14 | 2006-03-01 | Astrazeneca Ab | composto, métodos de tratamento de um humano ou animal, pela limitação da replicação de células, que sofre de cáncer, que sofre de uma doença neoplástica, e que se sofre de doenças proliferativas, uso de um composto, e, processo para a preparação de um composto ou de um seu sal farmaceuticamente aceitável ou de um éster hidrolisável in vivo do mesmo |
ES2702942T3 (es) * | 2003-04-17 | 2019-03-06 | Alnylam Pharmaceuticals Inc | Agentes de ARNi modificados |
ITMI20030821A1 (it) * | 2003-04-18 | 2004-10-19 | Internat Ct For Genetic En Gineering And | Polipeptidi chimerici e loro uso. |
US20050207998A1 (en) * | 2003-07-21 | 2005-09-22 | Yaoping Lu | Caffeine salt complexes and methods for using the same in the prevention or treatment of cancer |
MXPA06003110A (es) * | 2003-09-17 | 2006-06-20 | Icos Corp | Uso de inhibidores de chk1 para controlar la proliferacion celular. |
-
2006
- 2006-02-16 SI SI200630659T patent/SI1853721T1/sl unknown
- 2006-02-16 MX MX2007010073A patent/MX2007010073A/es active IP Right Grant
- 2006-02-16 BR BRPI0607798-6A patent/BRPI0607798A2/pt not_active IP Right Cessation
- 2006-02-16 ES ES06709785T patent/ES2341796T3/es active Active
- 2006-02-16 CA CA002598185A patent/CA2598185A1/en not_active Abandoned
- 2006-02-16 WO PCT/GB2006/000548 patent/WO2006087557A1/en active Application Filing
- 2006-02-16 US US11/816,128 patent/US20080145358A1/en not_active Abandoned
- 2006-02-16 JP JP2007555699A patent/JP2008530575A/ja active Pending
- 2006-02-16 AT AT06709785T patent/ATE464395T1/de active
- 2006-02-16 DK DK06709785.7T patent/DK1853721T3/da active
- 2006-02-16 AU AU2006215413A patent/AU2006215413B2/en not_active Ceased
- 2006-02-16 CN CNA2006800052527A patent/CN101120096A/zh active Pending
- 2006-02-16 PL PL06709785T patent/PL1853721T3/pl unknown
- 2006-02-16 EP EP06709785A patent/EP1853721B1/en active Active
- 2006-02-16 KR KR1020077018373A patent/KR20070107034A/ko not_active Ceased
- 2006-02-16 PT PT06709785T patent/PT1853721E/pt unknown
- 2006-02-16 DE DE602006013604T patent/DE602006013604D1/de active Active
- 2006-02-16 NZ NZ556718A patent/NZ556718A/en not_active IP Right Cessation
-
2007
- 2007-07-26 IL IL184873A patent/IL184873A0/en unknown
- 2007-08-10 ZA ZA200706670A patent/ZA200706670B/xx unknown
- 2007-09-11 NO NO20074610A patent/NO20074610L/no not_active Application Discontinuation
-
2008
- 2008-03-03 HK HK08102350.2A patent/HK1113059A1/xx not_active IP Right Cessation
-
2010
- 2010-05-31 HR HR20100313T patent/HRP20100313T1/hr unknown
- 2010-06-09 CY CY20101100544T patent/CY1110076T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
DE602006013604D1 (de) | 2010-05-27 |
IL184873A0 (en) | 2007-12-03 |
PL1853721T3 (pl) | 2010-08-31 |
US20080145358A1 (en) | 2008-06-19 |
AU2006215413A1 (en) | 2006-08-24 |
ZA200706670B (en) | 2008-10-29 |
MX2007010073A (es) | 2007-10-10 |
WO2006087557A1 (en) | 2006-08-24 |
AU2006215413B2 (en) | 2010-10-07 |
NO20074610L (no) | 2007-11-14 |
DK1853721T3 (da) | 2010-06-14 |
EP1853721B1 (en) | 2010-04-14 |
CN101120096A (zh) | 2008-02-06 |
NZ556718A (en) | 2010-10-29 |
JP2008530575A (ja) | 2008-08-07 |
PT1853721E (pt) | 2010-06-08 |
EP1853721A1 (en) | 2007-11-14 |
BRPI0607798A2 (pt) | 2010-06-22 |
ES2341796T3 (es) | 2010-06-28 |
CY1110076T1 (el) | 2015-01-14 |
HRP20100313T1 (hr) | 2010-07-31 |
KR20070107034A (ko) | 2007-11-06 |
HK1113059A1 (en) | 2008-09-19 |
ATE464395T1 (de) | 2010-04-15 |
CA2598185A1 (en) | 2006-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1113059A1 (en) | Method for determining responsiveness to chk1 inhibitors | |
ATE438853T1 (de) | Diagnostische testvorrichtung | |
WO2008131047A3 (en) | Plasminogen activator inhibitor-1 inhibitors and methods of use thereof to modulate lipid metabolism | |
WO2008054827A3 (en) | Bruton's tyrosine kinase activity probe and method of using | |
WO2009015233A3 (en) | Gefitinib sensitivity-related gene expression and products and methods related thereto | |
EA200901313A1 (ru) | Ингибиторы тирозинкиназы брутона | |
EP2100899A3 (en) | Compounds for proteasome enzyme inhibition | |
WO2007067968A3 (en) | Effects of inhibitors of fgfr3 on gene transcription | |
WO2008138578A3 (en) | Methods, kits, and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy | |
MX2007006640A (es) | Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina. | |
GB0203446D0 (en) | Detection and/or monitoring of synuclein-related diseases | |
WO2008088854A3 (en) | Genetic markers for predicting responsiveness to combination therapy | |
WO2007114986A3 (en) | Cooperative probes and methods of using them | |
ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
WO2008073177A3 (en) | Expression profiles associated with irinotecan treatment | |
EP1692102A4 (en) | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND SUFFERING RELATED TO CHEMOKIN RECEPTORS | |
FR13C0024I1 (fr) | Combinaisons antitumorales contenant vegf-trap et du 5fu ou un de ses derives | |
EP1893967A4 (en) | METHODS AND APPARATUS FOR ENHANCING THE SENSITIVITY OF ZERO CAPILLARY ELECTROPHORESIS | |
EP1931394A4 (en) | APOE4 DOMAIN INTERACTION HEMMER AND APPLICATION METHOD THEREFOR | |
EP1994172A4 (en) | METHOD FOR THE DIAGNOSIS AND / OR PREDICTION OF THE DEVELOPMENT OF ALLERGIC DISEASE AND AGENTS FOR TREATMENT AND / OR PREVENTING THEREOF | |
WO2008081094A3 (fr) | Methode de mesure fonctionnelle de l'activite de la thrombomoduline plasmatique | |
WO2005113797A3 (en) | METHODS FOR DETECTING Lp-PLA2 ACTIVITY AND INHIBITION OF Lp-PLA2 ACTIVITY | |
ATE333521T1 (de) | Detektion von vancomycin-resistenten enterococcus-subspezies | |
IL181192A0 (en) | Method for measuring dynamics of self-assembling systems of biological molecules in vivo and uses for discovering or evaluating therapeutic agents | |
WO2009140508A3 (en) | Methods for predicting a patient's response to egfr inhibitors |